98%
921
2 minutes
20
Cell technologies have provided promising tools for modulating the properties of multipotent mesenchymal stem/stromal cells (MSCs) to meet the needs of cell therapy as well as tissue engineering and regenerative medicine (TERM). Ex vivo preconditioning is directed at enhancing the engraftment of MSCs and activating their secretory activity, primarily the production of soluble mediators. The present review aims to highlight the underestimated effect of the most accepted preconditioning approaches on the modification of the important set of insoluble molecules secreted by MSCs into extracellular space-the extracellular matrix (ECM). A thorough review of the published literature was performed, with particular emphasis on ECM-related data. The analysis of data on ECM changes showed that most of the applied preconditioning methods-hypoxia, inflammatory priming, pharmacological agents, 3D culture, and scaffolds-generally stimulate ECM production, increase the deposition of growth factors, promote alignment, and increase ECM stiffness. There are already preliminary results demonstrating the successful application of preconditioned ECM for promoting angiogenesis, targeted stromal lineage differentiation, and other therapeutic goals. The prospects for further research in this area are discussed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12250167 | PMC |
http://dx.doi.org/10.3390/ijms26136301 | DOI Listing |
Mol Ther
September 2025
Be Biopharma, Cambridge, MA, 02139, USA. Electronic address:
Hemophilia B gene therapy treatments currently have not addressed the need for predictable, durable, active, and redosable factor IX (FIX). Unlike conventional gene therapy, engineered B Cell Medicines (BCMs) are durable, redosable, and titratable, and thus have the potential to address significant unmet needs in the Hemophilia B treatment paradigm. BE-101 is an autologous BCM comprised of expanded and differentiated B lymphocyte lineage cells genetically engineered ex vivo to secrete FIX-Padua.
View Article and Find Full Text PDFBiology (Basel)
August 2025
Stem Cell Laboratory, National Center for Biotechnology, Astana 010000, Kazakhstan.
Mesenchymal stem cells (MSCs) are a type of multipotent, non-hematopoietic cells of mesodermal origin. Due to their strong immunomodulatory, immunosuppressive, and regenerative potential, MSCs are used in cell therapy for inflammatory, immune-mediated, and degenerative diseases. Exosomes derived from MSCs have several advantages over MSC therapy, including non-immunogenicity, lack of infusion toxicity, ease of isolation, manipulation, and storage, cargo specificity, and the absence of tumor-forming potential and ethical concerns.
View Article and Find Full Text PDFDiabetologia
September 2025
Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain.
Aims/hypothesis: The aim of this study was to investigate whether basic fibroblast growth factor (bFGF) can restore the proliferation and migration capacities of adipose-derived stem cells (ASCs), which are impaired by type 2 diabetes, and improve vascular remodelling.
Methods: ASCs obtained from individuals with or without diabetes were cultured with 10 ng/ml bFGF for 9 days. The ASCs were phenotypically characterised and functionally tested for proliferation capacity.
Biochem Biophys Res Commun
September 2025
School of Anesthesia, Guizhou Medical University, Guiyang, China.
Reperfusion arrhythmia (RA) poses a significant risk to the prognosis of patients undergoing extracorporeal circulation cardiac surgery, and its occurrence closely linked to disturbances in myocardial electrical conduction. Our prior research indicated that ischemia-reperfusion (I/R) affects the localization of connexin 43 (Cx43) at the intercalated discs (IDs) by inducing depolymerization of microtubules, resulting in myocardial electrical conduction abnormalities in rats. Although sevoflurane preconditioning (SPC) has demonstrated considerable protective effects on ischemic myocardium, the underlying mechanisms remain inadequately understood.
View Article and Find Full Text PDFFront Pharmacol
August 2025
Department of Neonatology Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Chongq
Objective: This study aimed to investigate whether heliox preconditioning (HePC) alleviates neonatal acute respiratory distress syndrome (ARDS) by inhibiting oxidative stress and apoptosis, and to explore its potential mechanism.
Methods: Blood samples and bronchoalveolar lavage fluid (BALF) were collected from rat pups were randomly divided into control group, sham group, ARDS group, ARDS + CaMKII group, ARDS + CaMKII group, and ARDS + HePC group. We also investigated the role of CaMKII by manipulating its expression .